---
title: "Nature：全球癌症细胞疗法临床趋势"
date: 2025-11-12T03:51:18Z
draft: ["false"]
tags: [
  "fetched",
  "人体蛋白质组导航计划"
]
categories: ["Acdemic"]
---
Nature：全球癌症细胞疗法临床趋势 by 人体蛋白质组导航计划
------
<div><p data-pm-slice="0 0 []"><span><span leaf=""><span textstyle="">11</span></span></span><span leaf=""><span textstyle="">月</span></span><span><span leaf=""><span textstyle="">5</span></span></span><span leaf=""><span textstyle="">日，</span></span><span><span leaf=""><span textstyle="">Nature Reviews Drug Discovery</span></span></span><span leaf=""><span textstyle="">发布了一份研究报告，梳理了截至</span></span><span><span leaf=""><span textstyle="">2025</span></span></span><span leaf=""><span textstyle="">年</span></span><span><span leaf=""><span textstyle="">6</span></span></span><span leaf=""><span textstyle="">月的全球癌症细胞疗法临床试验数据。</span></span></p><p><span leaf=""><span textstyle="">该研究由美国癌症研究所</span><span textstyle="">（</span></span><span><span leaf=""><span textstyle="">C</span></span><span leaf=""><span textstyle="">RI</span></span></span><span leaf=""><span textstyle="">）</span><span textstyle="">团队完成，通过试验阶段、适应症、治疗模式、细胞来源及靶点等多个维度，勾勒出这一领域从</span></span><span><span leaf=""><span textstyle="">“</span></span></span><span leaf=""><span textstyle="">快速扩张</span></span><span><span leaf=""><span textstyle="">”</span></span></span><span leaf=""><span textstyle="">转向</span></span><span><span leaf=""><span textstyle="">“</span></span></span><span leaf=""><span textstyle="">稳步整合</span></span><span><span leaf=""><span textstyle="">”</span></span></span><span leaf=""><span textstyle="">的核心趋势。</span></span></p><p><span leaf=""><br></span><b><b><span leaf="" data-pm-slice='1 1 ["para",{"tagName":"p","attributes":{"class":"MsoNormal","style":"margin-left: 8px; margin-right: 8px; font-family: Helvetica Neue, Helvetica, Hiragino Sans GB, Microsoft YaHei, Arial, sans-serif;"},"namespaceURI":"http://www.w3.org/1999/xhtml"},"node",{"tagName":"b","attributes":{"style":"font-family: Helvetica Neue, Helvetica, Hiragino Sans GB, Microsoft YaHei, Arial, sans-serif;"},"namespaceURI":"http://www.w3.org/1999/xhtml"}]'><span textstyle="">全球格局和试验动态</span></span></b></b></p><p><b><span leaf=""><img alt="图片" data-ratio="0.08387698042870456" data-s="300,640" data-src="https://mmbiz.qpic.cn/mmbiz_png/1SqxY3bYAGK2Q7mw6VqGfzoEVibcqDtCCtQm036o997RuaNEjRT0Ozhf691M9ibMR7SPXElFZiajNsiaw64a5DtiaHg/640?wx_fmt=png&amp;wxfrom=13&amp;wx_lazy=1&amp;wx_co=1&amp;tp=wxpic#imgIndex=3" data-type="png" data-w="1073" src="https://mmbiz.qpic.cn/mmbiz_png/1SqxY3bYAGK2Q7mw6VqGfzoEVibcqDtCCtQm036o997RuaNEjRT0Ozhf691M9ibMR7SPXElFZiajNsiaw64a5DtiaHg/640?wx_fmt=png&amp;wxfrom=13&amp;wx_lazy=1&amp;wx_co=1&amp;tp=wxpic#imgIndex=3"></span></b></p><p><b><span leaf=""><br></span><span><p></p></span></b></p><p><span><span leaf=""><span textstyle="">CRI</span></span></span><span leaf=""><span textstyle="">免疫肿瘤学情报数据库共收录</span></span><span><span leaf=""><span textstyle="">6474</span></span></span><span leaf=""><span textstyle="">项干预性癌症细胞疗法试验，其中</span></span><span><span leaf=""><span textstyle="">1949</span></span></span><span leaf=""><span textstyle="">项已完成，</span></span><span><span leaf=""><span textstyle="">2628</span></span></span><span leaf=""><span textstyle="">项仍在进行中。其余试验处于计划、终止、撤回或暂停状态，总共涉及</span></span><span><span leaf=""><span textstyle="">3000</span></span></span><span leaf=""><span textstyle="">多种独特产品。</span></span><span><p></p></span></p><p><span leaf=""><span textstyle="">在目前仍在进行试验中，有</span></span><span><span leaf=""><span textstyle="">117</span></span></span><span leaf=""><span textstyle="">项评估的是美国</span></span><span><span leaf=""><span textstyle="">FDA</span></span></span><span leaf=""><span textstyle="">已批准的</span></span><span><span leaf=""><span textstyle="">CAR-T</span></span></span><span leaf=""><span textstyle="">、</span></span><span><span leaf=""><span textstyle="">TIL</span></span></span><span leaf=""><span textstyle="">或</span></span><span><span leaf=""><span textstyle="">TCR-T</span></span></span><span leaf=""><span textstyle="">产品，此外还有涉及这些药物的试验已完成或处于计划中。</span></span><span><p></p></span></p><p><span leaf=""><span textstyle="">新启动的细胞疗法试验数量在</span></span><span><span leaf=""><span textstyle="">2021</span></span></span><span leaf=""><span textstyle="">年达到顶峰</span></span><span leaf=""><span textstyle="">（</span></span><span><span leaf=""><span textstyle="">548</span></span></span><span leaf=""><span textstyle="">项）</span></span><span leaf=""><span textstyle="">，此后稳定在每年约</span></span><span><span leaf=""><span textstyle="">500-530</span></span></span><span leaf=""><span textstyle="">项，表明该领域正在走向成熟，初期的热情已转化为更具针对性的临床开发。</span></span><span><p></p></span></p><p><b><span data-pm-slice='4 5 ["para",{"tagName":"section","attributes":{"style":"-webkit-tap-highlight-color: transparent; margin: 0px 8px 24px; padding: 0px; outline: 0px; max-width: 100%; box-sizing: border-box !important; overflow-wrap: break-word !important; color: rgb(34, 34, 34); letter-spacing: 0.544px; white-space: normal; font-family: -apple-system-font, BlinkMacSystemFont, \"Helvetica Neue\", \"PingFang SC\", \"Hiragino Sans GB\", \"Microsoft YaHei UI\", \"Microsoft YaHei\", Arial, sans-serif; font-size: 16px; text-align: start; min-height: 1em; background-color: rgb(255, 255, 255); line-height: 2em;","data-pm-slice":"0 0 []"},"namespaceURI":"http://www.w3.org/1999/xhtml"}]'><strong><span><span leaf=""><span textstyle="">▌</span></span></span></strong></span><span leaf=""><span textstyle="">试验阶段与资助情况</span></span><span><p></p></span></b></p><p><span><span leaf=""><span textstyle="">I</span></span></span><span leaf=""><span textstyle="">期试验曾是细胞疗法研发的</span></span><span><span leaf=""><span textstyle="">“</span></span></span><span leaf=""><span textstyle="">主力军</span></span><span><span leaf=""><span textstyle="">”</span></span></span><span leaf=""><span textstyle="">，但自</span></span><span><span leaf=""><span textstyle="">2021</span></span></span><span leaf=""><span textstyle="">年以来占比下降近</span></span><span><span leaf=""><span textstyle="">20%</span></span></span><span leaf=""><span textstyle="">，反映出行业对研发管线的筛选更严格，早期项目整合趋势明显。与之相对，</span></span><span><span leaf=""><span textstyle="">II</span></span></span><span leaf=""><span textstyle="">期试验在</span></span><span><span leaf=""><span textstyle="">2023</span></span></span><span leaf=""><span textstyle="">年迎来强劲反弹</span></span><span leaf=""><span textstyle="">（得益于早期候选疗法推进）</span></span><span leaf=""><span textstyle="">，不过</span></span><span><span leaf=""><span textstyle="">2024</span></span></span><span leaf=""><span textstyle="">年增速略有放缓；而</span></span><span><span leaf=""><span textstyle="">III</span></span></span><span leaf=""><span textstyle="">期试验数量始终偏少，表明将细胞疗法推进至后期研发阶段仍面临技术与成本等多重挑战。</span></span><span><p></p></span></p><p><span leaf=""><span textstyle="">从资助来源看，工业界资助的试验占比稳定在</span></span><span><span leaf=""><span textstyle="">1/3</span></span></span><span leaf=""><span textstyle="">左右，每年保持</span></span><span><span leaf=""><span textstyle="">190-220</span></span></span><span leaf=""><span textstyle="">项的规模，未受整体试验增速放缓影响。反观学术界</span></span><span><span leaf=""><span textstyle="">/</span></span></span><span leaf=""><span textstyle="">政府资助的研究，自</span></span><span><span leaf=""><span textstyle="">2021</span></span></span><span leaf=""><span textstyle="">年以来活跃度下降超</span></span><span><span leaf=""><span textstyle="">14%</span></span></span><span leaf=""><span textstyle="">，成为推动总体试验启动数量减少的主要原因，这表明企业对细胞疗法的长期信心未减，当前调整更多是行业整体策略优化的结果。</span></span></p><section nodeleaf=""><img data-src="https://mmbiz.qpic.cn/mmbiz_png/sY9kTCVHfnkqpyOYibHkYib3mcyC5wI7Sat9yic3FQnpoIiaGu5y2U8gWh3RsnqCY24Q2iacOOx8FibicMvqXicG755bGg/640?wx_fmt=png&amp;from=appmsg&amp;tp=wxpic&amp;wxfrom=5&amp;wx_lazy=1#imgIndex=3" alt="图片" data-ratio="0.6649282920469362" data-s="300,640" data-type="png" data-w="767" type="block" data-imgfileid="100049536" src="https://mmbiz.qpic.cn/mmbiz_png/sY9kTCVHfnkqpyOYibHkYib3mcyC5wI7Sat9yic3FQnpoIiaGu5y2U8gWh3RsnqCY24Q2iacOOx8FibicMvqXicG755bGg/640?wx_fmt=png&amp;from=appmsg&amp;tp=wxpic&amp;wxfrom=5&amp;wx_lazy=1#imgIndex=3"></section><p><span leaf=""><span textstyle="">图</span></span><span leaf=""><span textstyle="">1. </span></span><span leaf=""><span textstyle="">全球介入性细胞疗法试验概览</span></span><span><p></p></span></p><p><b><b data-pm-slice='5 2 ["para",{"tagName":"p","attributes":{"class":"MsoNormal","style":"margin-left: 8px; margin-right: 8px; font-family: Helvetica Neue, Helvetica, Hiragino Sans GB, Microsoft YaHei, Arial, sans-serif;"},"namespaceURI":"http://www.w3.org/1999/xhtml"}]'><span data-pm-slice='4 5 ["para",{"tagName":"section","attributes":{"style":"-webkit-tap-highlight-color: transparent; margin: 0px 8px 24px; padding: 0px; outline: 0px; max-width: 100%; box-sizing: border-box !important; overflow-wrap: break-word !important; color: rgb(34, 34, 34); letter-spacing: 0.544px; white-space: normal; font-family: -apple-system-font, BlinkMacSystemFont, \"Helvetica Neue\", \"PingFang SC\", \"Hiragino Sans GB\", \"Microsoft YaHei UI\", \"Microsoft YaHei\", Arial, sans-serif; font-size: 16px; text-align: start; min-height: 1em; background-color: rgb(255, 255, 255); line-height: 2em;","data-pm-slice":"0 0 []"},"namespaceURI":"http://www.w3.org/1999/xhtml"}]'><strong><span><span leaf=""><span textstyle="">▌</span></span></span></strong></span></b><span leaf=""><span textstyle="">疾病适应症的转变</span></span><span><p></p></span></b></p><p><span leaf=""><span textstyle="">血液恶性肿瘤仍是最大适应症类别，但自</span></span><span><span leaf=""><span textstyle="">2020</span></span></span><span leaf=""><span textstyle="">年达到峰值后持续收缩，仅在</span></span><span><span leaf=""><span textstyle="">2024</span></span></span><span leaf=""><span textstyle="">年略有回升。针对混合实体瘤类型的疗法试验在</span></span><span><span leaf=""><span textstyle="">2019</span></span></span><span leaf=""><span textstyle="">年至</span></span><span><span leaf=""><span textstyle="">2023</span></span></span><span leaf=""><span textstyle="">年间显著扩大，随后在</span></span><span><span leaf=""><span textstyle="">2024</span></span></span><span leaf=""><span textstyle="">年急剧下降。</span></span><span><p></p></span></p><p><span leaf=""><span textstyle="">胃肠道癌症试验在</span></span><span><span leaf=""><span textstyle="">2021</span></span></span><span leaf=""><span textstyle="">年见顶后于</span></span><span><span leaf=""><span textstyle="">2024</span></span></span><span leaf=""><span textstyle="">年下降，而中枢神经系统肿瘤试验数量则稳步增加。乳腺癌试验在</span></span><span><span leaf=""><span textstyle="">2021</span></span></span><span leaf=""><span textstyle="">年跌入低谷后也出现小幅反弹。这些变化表明，行业或因开发广谱实体瘤细胞疗法面临挑战，正逐渐转向更具适应症特异性的研发策略。</span></span><span><p></p></span></p><p data-pm-slice="2 3 []"><span leaf=""><br></span><b><b><b><b><span leaf="" data-pm-slice='1 1 ["para",{"tagName":"p","attributes":{"class":"MsoNormal","style":"margin-left: 8px; margin-right: 8px; font-family: Helvetica Neue, Helvetica, Hiragino Sans GB, Microsoft YaHei, Arial, sans-serif;"},"namespaceURI":"http://www.w3.org/1999/xhtml"},"node",{"tagName":"b","attributes":{"style":"font-family: Helvetica Neue, Helvetica, Hiragino Sans GB, Microsoft YaHei, Arial, sans-serif;"},"namespaceURI":"http://www.w3.org/1999/xhtml"}]'><span textstyle="">治疗模式与靶点趋势</span></span></b></b></b></b></p><p><b><span leaf=""><img data-src="https://mmbiz.qpic.cn/mmbiz_png/1SqxY3bYAGK2Q7mw6VqGfzoEVibcqDtCCtQm036o997RuaNEjRT0Ozhf691M9ibMR7SPXElFZiajNsiaw64a5DtiaHg/640?wx_fmt=png&amp;wxfrom=5&amp;wx_lazy=1&amp;wx_co=1&amp;tp=wxpic#imgIndex=3" alt="图片" data-ratio="0.08387698042870456" data-s="300,640" data-type="png" data-w="1073" src="https://mmbiz.qpic.cn/mmbiz_png/1SqxY3bYAGK2Q7mw6VqGfzoEVibcqDtCCtQm036o997RuaNEjRT0Ozhf691M9ibMR7SPXElFZiajNsiaw64a5DtiaHg/640?wx_fmt=png&amp;wxfrom=5&amp;wx_lazy=1&amp;wx_co=1&amp;tp=wxpic#imgIndex=3"></span></b></p><p><b><span leaf=""><br></span><span><p></p></span></b></p><p><span leaf=""><span textstyle="">对</span></span><span><span leaf=""><span textstyle="">2019-2024</span></span></span><span leaf=""><span textstyle="">年治疗模式的分析显示，不同技术平台的发展态势各异。</span></span><span><p></p></span></p><section nodeleaf=""><img data-src="https://mmbiz.qpic.cn/mmbiz_png/sY9kTCVHfnkqpyOYibHkYib3mcyC5wI7Sa39uPo92F5NAIbqXQDiaYLbSyNicMCNpj8FORzbyPaKwH7Ejuq6C8t00Q/640?wx_fmt=png&amp;from=appmsg&amp;tp=wxpic&amp;wxfrom=5&amp;wx_lazy=1#imgIndex=5" alt="图片" data-ratio="0.9960886571056062" data-s="300,640" data-type="png" data-w="767" type="block" data-imgfileid="100049537" src="https://mmbiz.qpic.cn/mmbiz_png/sY9kTCVHfnkqpyOYibHkYib3mcyC5wI7Sa39uPo92F5NAIbqXQDiaYLbSyNicMCNpj8FORzbyPaKwH7Ejuq6C8t00Q/640?wx_fmt=png&amp;from=appmsg&amp;tp=wxpic&amp;wxfrom=5&amp;wx_lazy=1#imgIndex=5"></section><p><span leaf=""><span textstyle="">图</span></span><span><span leaf=""><span textstyle="">2. </span></span></span><span leaf=""><span textstyle="">不同治疗类型和年份时，癌症细胞疗法管线的变化</span></span></p><section data-pm-slice="0 0 []"><span><strong><span><span leaf=""><span textstyle="">▌</span></span></span></strong><strong><span><b><span leaf="" data-pm-slice='1 1 ["para",{"tagName":"p","attributes":{"class":"MsoNormal","style":"margin-left: 8px; margin-right: 8px; font-family: Helvetica Neue, Helvetica, Hiragino Sans GB, Microsoft YaHei, Arial, sans-serif;"},"namespaceURI":"http://www.w3.org/1999/xhtml"},"node",{"tagName":"b","attributes":{"style":"font-family: Helvetica Neue, Helvetica, Hiragino Sans GB, Microsoft YaHei, Arial, sans-serif;"},"namespaceURI":"http://www.w3.org/1999/xhtml"}]'><span textstyle="">治疗模式的演变</span></span></b></span></strong></span><span><p></p></span></section><p><b><span><span leaf=""><span textstyle="">CAR-T</span></span></span><span leaf=""><span textstyle="">细胞疗法</span></span></b><span leaf=""><span textstyle="">仍占主导地位，但首次出现持续性波动：试验数量在</span></span><span><span leaf=""><span textstyle="">2022</span></span></span><span leaf=""><span textstyle="">年达到峰值</span></span><span leaf=""><span textstyle="">（</span></span><span><span leaf=""><span textstyle="">277</span></span></span><span leaf=""><span textstyle="">项）</span></span><span leaf=""><span textstyle="">，</span></span><span><span leaf=""><span textstyle="">2023</span></span></span><span leaf=""><span textstyle="">年下降</span></span><span><span leaf=""><span textstyle="">12%</span></span></span><span leaf=""><span textstyle="">，</span></span><span><span leaf=""><span textstyle="">2024</span></span></span><span leaf=""><span textstyle="">年部分恢复</span></span><span leaf=""><span textstyle="">（</span></span><span><span leaf=""><span textstyle="">258</span></span></span><span leaf=""><span textstyle="">项）</span></span><span leaf=""><span textstyle="">。这一趋缓态势表明行业重心正从扩张转向优化，研发项目更侧重于改善疗法的持久性、生产制造和成本效益，而非单纯追求试验数量。</span></span><span><p></p></span></p><p><span leaf=""><span textstyle="">其他治疗模式也推动了该领域的多元化发展。</span></span><b><span><span leaf=""><span textstyle="">CAR-NK</span></span></span><span leaf=""><span textstyle="">细胞疗法</span></span></b><span leaf=""><span textstyle="">在六年内扩张近五倍</span></span><span leaf=""><span textstyle="">（从</span></span><span><span leaf=""><span textstyle="">2019</span></span></span><span leaf=""><span textstyle="">年</span></span><span><span leaf=""><span textstyle="">6</span></span></span><span leaf=""><span textstyle="">项增至</span></span><span><span leaf=""><span textstyle="">2024</span></span></span><span leaf=""><span textstyle="">年</span></span><span><span leaf=""><span textstyle="">29</span></span></span><span leaf=""><span textstyle="">项）</span></span><span leaf=""><span textstyle="">，尽管近期增速有所放缓。细胞癌症疫苗研发活动重现活力，从</span></span><span><span leaf=""><span textstyle="">2022</span></span></span><span leaf=""><span textstyle="">年的</span></span><span><span leaf=""><span textstyle="">32</span></span></span><span leaf=""><span textstyle="">项试验恢复至</span></span><span><span leaf=""><span textstyle="">2024</span></span></span><span leaf=""><span textstyle="">年的</span></span><span><span leaf=""><span textstyle="">59</span></span></span><span leaf=""><span textstyle="">项，接近其</span></span><span><span leaf=""><span textstyle="">2019</span></span></span><span leaf=""><span textstyle="">年</span></span><span><span leaf=""><span textstyle="">70</span></span></span><span leaf=""><span textstyle="">项的基线水平。</span></span><b><span leaf=""><span textstyle="">干细胞疗法</span></span></b><span leaf=""><span textstyle="">也反弹至</span></span><span><span leaf=""><span textstyle="">29</span></span></span><span leaf=""><span textstyle="">项试验，与</span></span><span><span leaf=""><span textstyle="">2021</span></span></span><span leaf=""><span textstyle="">年水平相当；而基于细菌的治疗药物和其他</span></span><b><span><span leaf=""><span textstyle="">NK</span></span></span><span leaf=""><span textstyle="">细胞</span></span><span><span leaf=""><span textstyle="">（非</span></span><span><span leaf=""><span textstyle="">CAR</span></span></span><span leaf=""><span textstyle="">）</span></span></span><span leaf=""><span textstyle="">疗法</span></span></b><span leaf=""><span textstyle="">则急剧下降。</span></span><span><p></p></span></p><p><span leaf=""><span textstyle="">其他</span></span><span><span leaf=""><span textstyle="">T</span></span></span><span leaf=""><span textstyle="">细胞疗法产品波动较大，在</span></span><span><span leaf=""><span textstyle="">2022</span></span></span><span leaf=""><span textstyle="">年达到</span></span><span><span leaf=""><span textstyle="">86</span></span></span><span leaf=""><span textstyle="">项试验的峰值后，于</span></span><span><span leaf=""><span textstyle="">2024</span></span></span><span leaf=""><span textstyle="">年收缩至</span></span><span><span leaf=""><span textstyle="">61</span></span></span><span leaf=""><span textstyle="">项。基于</span></span><span><span leaf=""><span textstyle="">T</span></span></span><span leaf=""><span textstyle="">细胞的亚型中，</span></span><b><span><span leaf=""><span textstyle="">γδ TCR-T</span></span></span><span leaf=""><span textstyle="">细胞疗法</span></span></b><span leaf=""><span textstyle="">试验从</span></span><span><span leaf=""><span textstyle="">2022</span></span></span><span leaf=""><span textstyle="">年的</span></span><span><span leaf=""><span textstyle="">1</span></span></span><span leaf=""><span textstyle="">项短暂扩增至</span></span><span><span leaf=""><span textstyle="">2023</span></span></span><span leaf=""><span textstyle="">年的</span></span><span><span leaf=""><span textstyle="">8</span></span></span><span leaf=""><span textstyle="">项，但在</span></span><span><span leaf=""><span textstyle="">2024</span></span></span><span leaf=""><span textstyle="">年回落至</span></span><span><span leaf=""><span textstyle="">1</span></span></span><span leaf=""><span textstyle="">项。这一急剧逆转可能预示着该技术目前面临开发障碍或临床可行性有限，暗示其向临床开发转化存在挑战。</span></span><b><span><span leaf=""><span textstyle="">TCR</span></span></span><span leaf=""><span textstyle="">工程化</span></span><span><span leaf=""><span textstyle="">T</span></span></span><span leaf=""><span textstyle="">细胞疗法</span></span></b><span leaf=""><span textstyle="">持续衰退，从</span></span><span><span leaf=""><span textstyle="">2022</span></span></span><span leaf=""><span textstyle="">年</span></span><span><span leaf=""><span textstyle="">35</span></span></span><span leaf=""><span textstyle="">项试验的峰值降至</span></span><span><span leaf=""><span textstyle="">2024</span></span></span><span leaf=""><span textstyle="">年的</span></span><span><span leaf=""><span textstyle="">21</span></span></span><span leaf=""><span textstyle="">项。相比之下，</span></span><span><span leaf=""><span textstyle="">TIL</span></span></span><span leaf=""><span textstyle="">产品试验表现出更强的稳定性。在</span></span><span><span leaf=""><span textstyle="">2023</span></span></span><span leaf=""><span textstyle="">年小幅下降后，其试验活动在</span></span><span><span leaf=""><span textstyle="">2024</span></span></span><span leaf=""><span textstyle="">年恢复了</span></span><span><span leaf=""><span textstyle="">12%</span></span></span><span leaf=""><span textstyle="">，达到</span></span><span><span leaf=""><span textstyle="">27</span></span></span><span leaf=""><span textstyle="">项，但仍低于</span></span><span><span leaf=""><span textstyle="">2022</span></span></span><span leaf=""><span textstyle="">年</span></span><span><span leaf=""><span textstyle="">31</span></span></span><span leaf=""><span textstyle="">项的峰值。</span></span><span><p></p></span></p><p><span leaf=""><span textstyle="">这些数据表明，试验启动总量的平台期背后，隐藏着管线内部持续的多样化趋势。</span></span><span><span leaf=""><span textstyle="">2022</span></span></span><span leaf=""><span textstyle="">年至</span></span><span><span leaf=""><span textstyle="">2024</span></span></span><span leaf=""><span textstyle="">年间，</span></span><span><span leaf=""><span textstyle="">CAR-T</span></span></span><span leaf=""><span textstyle="">细胞疗法试验数量下降了</span></span><span><span leaf=""><span textstyle="">6.9%</span></span></span><span leaf=""><span textstyle="">，其他</span></span><span><span leaf=""><span textstyle="">T</span></span></span><span leaf=""><span textstyle="">细胞疗法下降了</span></span><span><span leaf=""><span textstyle="">20.9%</span></span></span><span leaf=""><span textstyle="">。相比之下，细胞癌症疫苗增加了</span></span><span><span leaf=""><span textstyle="">81.3%</span></span></span><span leaf=""><span textstyle="">，干细胞疗法增加了</span></span><span><span leaf=""><span textstyle="">61.1%</span></span></span><span leaf=""><span textstyle="">，</span></span><span><span leaf=""><span textstyle="">CAR-NK</span></span></span><span leaf=""><span textstyle="">项目增长了</span></span><span><span leaf=""><span textstyle="">34.8%</span></span></span><span leaf=""><span textstyle="">，其中约</span></span><span><span leaf=""><span textstyle="">40%</span></span></span><span leaf=""><span textstyle="">现在针对实体瘤。</span></span><span><span leaf=""><span textstyle="">CAR-T</span></span></span><span leaf=""><span textstyle="">细胞疗法试验仍主要瞄准血液疾病，在实体瘤领域的扩展有限。</span></span><span><p></p></span></p><p><b><b data-pm-slice='5 2 ["para",{"tagName":"p","attributes":{"class":"MsoNormal","style":"margin-left: 8px; margin-right: 8px; font-family: Helvetica Neue, Helvetica, Hiragino Sans GB, Microsoft YaHei, Arial, sans-serif;"},"namespaceURI":"http://www.w3.org/1999/xhtml"}]'><span data-pm-slice='4 5 ["para",{"tagName":"section","attributes":{"style":"-webkit-tap-highlight-color: transparent; margin: 0px 8px 24px; padding: 0px; outline: 0px; max-width: 100%; box-sizing: border-box !important; overflow-wrap: break-word !important; color: rgb(34, 34, 34); letter-spacing: 0.544px; white-space: normal; font-family: -apple-system-font, BlinkMacSystemFont, \"Helvetica Neue\", \"PingFang SC\", \"Hiragino Sans GB\", \"Microsoft YaHei UI\", \"Microsoft YaHei\", Arial, sans-serif; font-size: 16px; text-align: start; min-height: 1em; background-color: rgb(255, 255, 255); line-height: 2em;","data-pm-slice":"0 0 []"},"namespaceURI":"http://www.w3.org/1999/xhtml"}]'><strong><span><span leaf=""><span textstyle="">▌</span></span></span></strong></span></b><span leaf=""><span textstyle="">自体与同种异体细胞来源</span></span><span><p></p></span></b></p><p><span><span leaf=""><span textstyle="">CAR-T</span></span></span><span leaf=""><span textstyle="">细胞的来源也呈现出对比鲜明的趋势。自体</span></span><span><span leaf=""><span textstyle="">CAR-T</span></span></span><span leaf=""><span textstyle="">细胞产品在</span></span><span><span leaf=""><span textstyle="">2024</span></span></span><span leaf=""><span textstyle="">年下降了近</span></span><span><span leaf=""><span textstyle="">12%</span></span></span><span leaf=""><span textstyle="">，逆转了</span></span><span><span leaf=""><span textstyle="">2023</span></span></span><span leaf=""><span textstyle="">年</span></span><span><span leaf=""><span textstyle="">7%</span></span></span><span leaf=""><span textstyle="">的温和增长。而同种异体方法则保持稳定，在经历上一年度</span></span><span><span leaf=""><span textstyle="">11%</span></span></span><span leaf=""><span textstyle="">的下降后，</span></span><span><span leaf=""><span textstyle="">2024</span></span></span><span leaf=""><span textstyle="">年小幅增长</span></span><span><span leaf=""><span textstyle="">1.6%</span></span></span><span leaf=""><span textstyle="">。</span></span><span><p></p></span></p><p><b><b data-pm-slice='5 2 ["para",{"tagName":"p","attributes":{"class":"MsoNormal","style":"margin-left: 8px; margin-right: 8px; font-family: Helvetica Neue, Helvetica, Hiragino Sans GB, Microsoft YaHei, Arial, sans-serif;"},"namespaceURI":"http://www.w3.org/1999/xhtml"}]'><span data-pm-slice='4 5 ["para",{"tagName":"section","attributes":{"style":"-webkit-tap-highlight-color: transparent; margin: 0px 8px 24px; padding: 0px; outline: 0px; max-width: 100%; box-sizing: border-box !important; overflow-wrap: break-word !important; color: rgb(34, 34, 34); letter-spacing: 0.544px; white-space: normal; font-family: -apple-system-font, BlinkMacSystemFont, \"Helvetica Neue\", \"PingFang SC\", \"Hiragino Sans GB\", \"Microsoft YaHei UI\", \"Microsoft YaHei\", Arial, sans-serif; font-size: 16px; text-align: start; min-height: 1em; background-color: rgb(255, 255, 255); line-height: 2em;","data-pm-slice":"0 0 []"},"namespaceURI":"http://www.w3.org/1999/xhtml"}]'><strong><span><span leaf=""><span textstyle="">▌</span></span></span></strong></span></b><span leaf=""><span textstyle="">靶点演变与多样化</span></span><span><p></p></span></b></p><p><span><span leaf=""><span textstyle="">CD19</span></span></span><span leaf=""><span textstyle="">和</span></span><span><span leaf=""><span textstyle="">BCMA</span></span></span><span leaf=""><span textstyle="">在</span></span><span><span leaf=""><span textstyle="">2024</span></span></span><span leaf=""><span textstyle="">年仍是</span></span><span><span leaf=""><span textstyle="">CAR-T</span></span></span><span leaf=""><span textstyle="">细胞疗法的主要靶点，但两者相关试验数量均出现下降。其他几个血液学靶点也大幅收缩，而</span></span><span><span leaf=""><span textstyle="">CD22</span></span></span><span leaf=""><span textstyle="">则增加了</span></span><span><span leaf=""><span textstyle="">33%</span></span></span><span leaf=""><span textstyle="">。</span></span><span><span leaf=""><span textstyle="">NKG2D</span></span></span><span leaf=""><span textstyle="">也下降了近</span></span><span><span leaf=""><span textstyle="">30%</span></span></span><span leaf=""><span textstyle="">。</span></span><span><p></p></span></p><p><span leaf=""><span textstyle="">相比之下，实体瘤相关靶点研发势头增强。</span></span><span><span leaf=""><span textstyle="">B7H3</span></span></span><span leaf=""><span textstyle="">的活跃度翻倍，而</span></span><span><span leaf=""><span textstyle="">HER2</span></span></span><span leaf=""><span textstyle="">和</span></span><span><span leaf=""><span textstyle="">GPC3</span></span></span><span leaf=""><span textstyle="">分别扩张了</span></span><span><span leaf=""><span textstyle="">40%</span></span></span><span leaf=""><span textstyle="">和</span></span><span><span leaf=""><span textstyle="">25%</span></span></span><span leaf=""><span textstyle="">。</span></span><span><span leaf=""><span textstyle="">GPRC5D</span></span></span><span leaf=""><span textstyle="">保持稳定，</span></span><span><span leaf=""><span textstyle="">NY-ESO-1</span></span></span><span leaf=""><span textstyle="">在一个新试验中重新出现。独特靶点总数从</span></span><span><span leaf=""><span textstyle="">2022</span></span></span><span leaf=""><span textstyle="">年的</span></span><span><span leaf=""><span textstyle="">106</span></span></span><span leaf=""><span textstyle="">个跃升至</span></span><span><span leaf=""><span textstyle="">2024</span></span></span><span leaf=""><span textstyle="">年的</span></span><span><span leaf=""><span textstyle="">130</span></span></span><span leaf=""><span textstyle="">个，创下迄今最大年度增幅，反映出行业正积极开发新抗原与多靶点构建体，以提升实体瘤疗效。</span></span><span><p></p></span></p><p data-pm-slice="2 3 []"><span leaf=""><br></span><b><b><b><span leaf="" data-pm-slice='1 1 ["para",{"tagName":"p","attributes":{"class":"MsoNormal","style":"margin-left: 8px; margin-right: 8px; font-family: Helvetica Neue, Helvetica, Hiragino Sans GB, Microsoft YaHei, Arial, sans-serif;"},"namespaceURI":"http://www.w3.org/1999/xhtml"},"node",{"tagName":"b","attributes":{"style":"font-family: Helvetica Neue, Helvetica, Hiragino Sans GB, Microsoft YaHei, Arial, sans-serif;"},"namespaceURI":"http://www.w3.org/1999/xhtml"}]'><span textstyle="">结论与展望</span></span></b></b></b></p><p><b><span leaf=""><img data-src="https://mmbiz.qpic.cn/mmbiz_png/1SqxY3bYAGK2Q7mw6VqGfzoEVibcqDtCCtQm036o997RuaNEjRT0Ozhf691M9ibMR7SPXElFZiajNsiaw64a5DtiaHg/640?wx_fmt=png&amp;wxfrom=5&amp;wx_lazy=1&amp;wx_co=1&amp;tp=wxpic#imgIndex=3" alt="图片" data-ratio="0.08387698042870456" data-s="300,640" data-type="png" data-w="1073" src="https://mmbiz.qpic.cn/mmbiz_png/1SqxY3bYAGK2Q7mw6VqGfzoEVibcqDtCCtQm036o997RuaNEjRT0Ozhf691M9ibMR7SPXElFZiajNsiaw64a5DtiaHg/640?wx_fmt=png&amp;wxfrom=5&amp;wx_lazy=1&amp;wx_co=1&amp;tp=wxpic#imgIndex=3"></span></b></p><p><b><span leaf=""><br></span><span><p></p></span></b></p><p><span leaf=""><span textstyle="">自</span></span><span><span leaf=""><span textstyle="">2021</span></span></span><span leaf=""><span textstyle="">年以来，癌症细胞疗法的临床试验活动趋于稳定，表明该领域正在走向成熟，而非收缩。</span></span><span><span leaf=""><span textstyle="">CAR-T</span></span></span><span leaf=""><span textstyle="">细胞仍是主导性技术，但如今正与日益增多的其他方法共存，包括</span></span><span><span leaf=""><span textstyle="">CAR-NK</span></span></span><span leaf=""><span textstyle="">细胞疗法、细胞癌症疫苗和干细胞疗法。探索性</span></span><span><span leaf=""><span textstyle="">T</span></span></span><span leaf=""><span textstyle="">细胞亚型的收缩以及</span></span><span><span leaf=""><span textstyle="">TIL</span></span></span><span leaf=""><span textstyle="">活动的稳定性表明，研发重点正向经过临床验证且可扩展的策略转移。</span></span><span><p></p></span></p><p><span leaf=""><span textstyle="">与此同时，细胞疗法研究的战略焦点正在发生变化。传统的血液学靶点大幅收缩，而实体瘤靶点抗原则势头正劲。靶点多样性创纪录地增加，反映了行业为克服实体瘤抗原异质性和免疫逃逸所付出的努力。</span></span><span><p></p></span></p><p><span leaf=""><span textstyle="">随着</span></span><span><span leaf=""><span textstyle="">CAR-T</span></span></span><span leaf=""><span textstyle="">细胞疗法扩展到更多治疗场景和新适应症，关于生产制造和资源分配的问题变得愈发重要，而双特异性抗体等竞争模式的增加更是加剧了这一挑战。监测临床发展趋势对引导该领域顺利度过整合阶段、支持患者获得有效细胞疗法至关重要。</span></span><span><p></p></span></p><p><b><span leaf=""><span textstyle="">参考资料：</span></span><span><p></p></span></b></p><p><span><span leaf=""><span textstyle="">Fahad Benthani et al. Cancer cell therapies: global clinical trial trends and emerging directions. Nature Reviews Drug Discovery</span></span></span><span leaf=""><span textstyle="">（</span></span><span><span leaf=""><span textstyle="">2025</span></span></span><span leaf=""><span textstyle="">）</span></span><span><p></p></span></p><p><span><span leaf=""><span textstyle="">https://www.nature.com/articles/d41573-025-00180-1</span></span></span></p><section><span leaf=""><span textstyle="">（文章来源于医药魔方Pro）</span></span></section><p><mp-style-type data-value="3"></mp-style-type></p></div>  
<hr>
<a href="https://mp.weixin.qq.com/s/1DLySeaPGkgWuiAk1Gjqrg",target="_blank" rel="noopener noreferrer">原文链接</a>
